Metastasis-directed radiotherapy for non-small cell lung cancer failured under TKI: A case report and literature review

Basit Öğe Kaydı
dc.authoridKahvecioglu, Alper/0000-0001-8714-2383
dc.contributor.authorKahvecioglu, A.
dc.contributor.authorKilickap, S.
dc.contributor.authorHurmuz, P.
dc.date.accessioned2024-05-19T14:38:56Z
dc.date.available2024-05-19T14:38:56Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractAlthough tyrosine kinase inhibitors (TKI) have revolutionized the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer (ALKr-NSCLC), radiotherapy (RT) still plays an essential role for treatment of both intracranial and extracranial metastases, particularly for patients experienced a TKI-failure. We reported the case of a 38-year-old woman with metastatic ALKr-NSCLC who received whole-brain radiotherapy (RT) for multiple brain metastases (BMs), initially. After RT, alectinib was initiated and the patient had a good clinico-radiological response in both intracranial and extracranial regions. However, intracranial progression was developed and, stereotactic radiosurgery (SRS) was applied to the four progressed BMs. Two months after SRS, all BMs disappeared. While patient was using alectinib, a recurrent lung lesion, a hilar lymph node and bone metastasis were detected. Stereotactic body radiother-apy (SBRT) was applied to all metastatic sites and, alectinib was continued again. Three months after SBRT, a complete response was obtained. She has been alive with the initial systemic therapy agent for more than 4 years without evidence of neither disease nor toxicity. SRS/SBRT may eradicate the TKI-resistant tumoral clones and it may prevent switching the systemic therapy, even if there is a failure. (c) 2023 Published by Elsevier Masson SAS on behalf of Societe franc,aise de radiotherapie oncologique (SFRO).en_US
dc.identifier.doi10.1016/j.canrad.2023.06.002
dc.identifier.endpage735en_US
dc.identifier.issn1278-3218
dc.identifier.issn1769-6658
dc.identifier.issue8en_US
dc.identifier.pmid37827958en_US
dc.identifier.scopus2-s2.0-85173669142en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage731en_US
dc.identifier.urihttps://doi.org10.1016/j.canrad.2023.06.002
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4655
dc.identifier.volume27en_US
dc.identifier.wosWOS:001127825200001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofCancer Radiotherapieen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectAlectiniben_US
dc.subjectBrain Metastasisen_US
dc.subjectLung Canceren_US
dc.subjectRadiotherapyen_US
dc.titleMetastasis-directed radiotherapy for non-small cell lung cancer failured under TKI: A case report and literature reviewen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu